Davide Campari-Milano (CPR) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
6 May, 2026Executive summary
Achieved +2.9% organic net sales growth in Q1 2026, with broad-based gains across regions and brands, supported by targeted inventory optimization in the US on non-priority brands.
Gained market share in almost all markets, with strong industry outperformance and positive sell-out trends in the US and Europe.
Accelerated innovation and geographic expansion, including launches like Aperol new bottle, Aperol RTD, and Campari Spritz RTS.
Inventory optimization in the US on non-priority brands impacted quarterly figures by EUR 10 million, but is minor relative to annual US sales.
APAC and GTR accounted for 7% of total sales, declining by 1.6% due to a 13.5% drop in GTR, while APAC grew 1.9%; Australia, China, and India posted solid growth.
Financial highlights
Q1 2026 organic net sales growth of +2.9% year-over-year, broad-based across all regions, with net sales at €643 million, down 3.4% year-over-year due to negative FX and perimeter effects.
Europe delivered +1.9% organic growth, led by the UK, Italy, and Germany; France impacted by a high comparison base.
North America grew +2.2% organically, with solid US trends and recovery in Jamaica, but offset by inventory optimization and weak cognac market.
Developing markets saw +12.7% organic growth, driven by Brazil and Argentina.
APAC & GTR: 7% of sales, -1.6% organic growth, with GTR down 13.5% and APAC up 1.9%.
Outlook and guidance
Full-year 2026 guidance confirmed at circa +3% topline growth, incorporating inventory optimization, ongoing volatility, and industry outperformance.
EBIT-adjusted margin accretion skewed to H2 due to front-loaded A&P investments and US tariff impacts (~€30 million for the year).
SG&A containment program to deliver up to 140bps margin benefit by end-2027.
Confident in balancing risks and opportunities, with continued investment in brands and innovation.
Monitoring cost inflation, logistics, and geopolitical risks, but current impact is limited.
Latest events from Davide Campari-Milano
- Organic sales up 2.4%, margin expansion, and a 54% dividend increase with improved leverage.CPR
Q4 20254 Mar 2026 - Solid H1 growth led by Americas and Global Priorities, with margin pressure from mix and capex.CPR
Q2 20242 Feb 2026 - Net sales up 2.1% YTD, EBIT margin down, with cost cuts, acquisitions, and portfolio focus underway.CPR
Q3 202418 Jan 2026 - Resilient 2024 growth and strong cash flow, but margin pressures and tariff risks ahead.CPR
Q4 202410 Dec 2025 - Q1 organic sales fell 4.2%, but APAC growth and cost actions support 2025 guidance.CPR
Q1 202520 Nov 2025 - Solid organic growth and margin resilience achieved despite macro headwinds, leverage at 2.9x.CPR
Q3 202530 Oct 2025 - Q2 organic growth and margin gains drive resilient H1, with guidance and deleveraging on track.CPR
Q2 202530 Oct 2025